PAS
HOWL icon

Point72 Asia (Singapore)’s Werewolf Therapeutics HOWL Stock Holding History

Point72 Asia (Singapore)’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$25.6K Sell
13,016
-7,110
-35% -$9.73K ﹤0.01% 666
2025
Q2 		$21.9K Buy
+20,126
New +$20.7K ﹤0.01% 720
2024
Q2 		– Sell
-23,264
Closed -$151K – 1225
2024
Q1 		$151K Buy
+23,264
New +$136K 0.04% 532

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asia (Singapore)'s HOWL Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Werewolf Therapeutics (HOWL) stake by 35% in Q3 2025, selling an estimated $9.73K and leaving 13,016 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Point72 Asia (Singapore) first reported a position in HOWL in Q1 2024 and has held it in 3 quarters since. The position peaked at $151K in Q1 2024. 62 funds tracked by Wall St. Rank hold HOWL as of Q3 2025.

  • Point72 Asia (Singapore) held 13,016 shares of Werewolf Therapeutics worth $25.6K as of Q3 2025.
  • Point72 Asia (Singapore) sold 7,110 Werewolf Therapeutics shares in Q3 2025, an estimated $9.73K.
  • Werewolf Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #666 holding.
  • Point72 Asia (Singapore) first reported a position in Werewolf Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Werewolf Therapeutics position peaked at $151K in Q1 2024.
  • 62 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.